San Diego Convention Center, San Diego, CA
December 3-6, 2016
Dana-Farber Cancer Institute
Dana-Farber/Boston Children’s Cancer and Blood Disorders Center
Paul Richardson, MD, gives an overview of multiple myeloma advances from ASH 2016.
Matthew Davids, MD, discusses a study he led showing encouraging results of a drug combination in patients with relapsed forms of leukemia or lymphoma.
Kenneth C. Anderson, MD, of Dana-Farber Cancer Institute, talks about becoming the 2017 President of the American Society of Hematology (ASH) and research to be presented at the 58th annual ASH meeting in San Diego.
Dana-Farber at ASH 2016
As leaders in blood and blood cancer research, physicians and scientists from Dana-Farber Cancer Institute and Dana-Farber/Boston Children's Cancer and Blood Disorders Center showcased their advances at the 58th Annual Meeting of the American Society of Hematology (ASH) in San Diego, California, in December of 2016.
As the premier conference in the field, the ASH Annual Meeting attracts more than 20,000 experts who share their advances in hematologic malignancies, including leukemia, lymphoma, and multiple myeloma, as well as other blood disorders.
Attendees visited our Dana-Farber and Dana-Farber/Boston Children’s booths to connect with our adult and pediatric physicians and scientists – and learn more about our discoveries, innovations, and clinical trials.
Dana-Farber Presentations at ASH 2016
Many faculty from Dana-Farber’s Center for Hematologic Oncology presented advances at ASH 2016.
View the schedule of select presentations.
Join the Twitter conversation at #ASH16
Follow us on LinkedIn
Dana-Farber experts were at our booth
Visitors to Dana-Farber's booth met one-on-one with specialists from our Adult Hematologic Malignancies program. Faculty members were available to answer questions, discuss a challenging case, or discuss advances covered at ASH:
Saturday, December 3
Jacqueline Garcia, MD
Expert in Acute Myeloid Leukemia
Saturday, December 3
Robert Soiffer, MD
Expert in Stem Cell Transplantation
Sunday, December 4
Jorge Castillo, MD
Expert in Waldenström's Macroglobulinemia
Sunday, December 4
Caron Jacobson, MD
Expert in Lymphoma
Monday, December 5
Jacob Laubach, MD
Expert in Multiple Myeloma
Dana-Farber research highlights from ASH 2016
Mutations in lymphoma patients undergoing transplants raise risk of second cancers
A significant percentage of lymphoma patients undergoing transplants with their own blood stem cells carry acquired genetic mutations that increase their risks of developing second hematologic cancers and dying from other causes, according to a study from Dana-Farber researchers.
Children with Down syndrome and acute lymphoblastic leukemia fare as well as other children treated on Dana-Farber ALL Consortium protocols
Despite an elevated risk of toxicity from chemotherapy, children with Down syndrome and acute lymphoblastic leukemia (ALL) did not experience higher rates of relapse or treatment-related mortality compared with other children treated on Dana-Farber ALL Consortium Protocols.
Immunotherapy agent yields full and partial remissions in patients with aggressive non-Hodgkin lymphomas, study finds
An immunotherapy drug able to induce lasting remissions in classical Hodgkin lymphoma may be equally effective in patients with two rare, aggressive forms of non-Hodgkin lymphoma, results from Dana-Farber researchers show.
Early treatment may prevent progression to multiple myeloma
Early intervention with an immunotherapy-based drug combination may prevent progression of high-risk “smoldering” multiple myeloma to the full-blown disease, according to researchers from Dana-Farber.
Drug combination yields encouraging results in patients with relapsed forms of leukemia or lymphoma in early stage study
A study led by Dana-Farber researchers shows a combination of two targeted agents has demonstrated safety as well as encouraging signs of effectiveness in a clinical trial in patients with relapsed or hard-to-treat chronic lymphocytic leukemia or mantle cell lymphoma.
Genetic classification offers guide to stem cell transplantation for patients with myelodysplastic syndrome
A blood test can indicate whether some patients with myelodysplastic syndrome (MDS) are likely to benefit from a stem cell transplant and, if so, whether the transplant should involve high or moderate doses of chemotherapy and/or radiation therapy, according to a study by scientists at Dana-Farber.
Select 2016 publications by Dana-Farber faculty
Highlights from Dana-Farber at ASH 2015
Paul Richardson, MD, delivered the 2015 Ernest Beutler Lecture, "Understanding the Proteasome: from Protein Degradation to Disease Therapy"
On December 7, conference attendees heard Paul Richardson, MD, clinical program leader and director of clinical research at Dana-Farber’s Jerome Lipper Multiple Myeloma Center and the R.J. Corman professor of Medicine at Harvard Medical School, as he presented ASH’s 2015 Ernest Beutler Lecture with Alfred Goldberg, PhD. The lecture topic was, "Understanding the Proteasome: from Protein Degradation to Disease Therapy."
Our conference presenters
At this year’s meeting, many renowned Dana-Farber and Dana-Farber/Boston Children’s experts in hematological malignancies and hematology shared their discoveries, innovations, and insights from their adult and pediatric research and clinical practice.
Download these rosters of select Dana-Farber and Dana-Farber/Boston Children’s conference speakers:
ASH 2015 Dana-Farber Speakers
ASH 2015 Dana-Farber/Boston Children's Speakers
Our leadership role in the American Society of Hematology (ASH)
At Dana-Farber and Dana-Farber/Boston Children’s, we’re proud of our leadership role – at the Annual Meeting, and in the Society itself. Dana-Farber/Boston Children’s pediatric oncologist David Williams, MD, is 2015 ASH president. And Dana-Farber medical oncologist Kenneth Anderson, MD, is 2015 ASH vice president and 2016 ASH president-elect.
Dana-Farber at ASH 2015: Media Highlights
ASCO POST Newsreel: 'Dana-Farber's Richard M. Stone, MD, discusses the RATIFY trial, an international prospective study on the survival impact of midostaurin, a multikinase inhibitor, in newly disagnosed acute myeloid leukemia with FLT3 mutations'
OncLive: 'Midostaurin Shows Rare Survival Improvement in FLT3-Mutated AML'
OncologyNurseAdvisor: 'Antibiotic Prophylaxis During Induction Phase Reduces Infections in Pediatric ALL'
Medscape: 'Rituximab + Chemo: New Standard of Care for BCP-ALL?'
Cancer Therapy Advisor: 'Nidostaurin Prolongs Survival in Patients with Newly Diagnosed AML'
Medscape: 'Midostaurin in AML: First Targeted Agent Improves Survival'
Dana-Farber research highlights from ASH 2015
Dana-Farber experts presented exciting new research findings at the 2015 conference. Presentations included:
- Studies highlight new drug targets or compounds for acute myeloid leukemia
Pre-clinical data unveiled across four studies presented at the 57th annual meeting of the American Society of Hematology highlight four potential treatment opportunities for acute myeloid leukemia (AML), a blood cancer accounting for approximately 20 percent of all childhood leukemias and 32 percent of adult leukemias. Dana-Farber senior investigator: Kimberly Stegmaier, MD.
- Three studies point to effectiveness of new combination therapies for relapsed or drug-resistant multiple myeloma
In a trio of studies presented at the 57th ASH Annual Meeting, Dana-Farber investigators presented the results of clinical trials showing that new drug combinations can significantly extend the time in which multiple myeloma is kept in check in patients with relapsed or treatment-resistant forms of the disease. Clinical program leader: Paul Richardson, MD.
- Experimental drug is first targeted therapy to improve survival in certain high-risk AML patients
Dana-Farber scientists report that midostaurin added to standard chemotherapy is the first targeted treatment to improve survival of a high-risk, genetically defined subgroup of patients with acute myeloid leukemia (AML). Dana-Farber presenter: Richard Stone, MD.
- Early gene therapy results in Wiskott-Aldrich syndrome promising
Researchers reported promising preliminary outcomes for the first four children enrolled in a U.S. gene therapy trial for Wiskott-Aldrich syndrome (WAS, a life-threatening genetic blood and immune disorder. All four boys have improved between nine and 24 months following treatment. Principal investigator: Sung Yun Pai, MD.
- Children with childhood leukemia benefit from prophylactic antibiotics
Prophylactic antibiotics significantly reduce the risk of serious bacterial infections in children during the critical first month of treatment for acute lymphoblastic leukemia (ALL), the most common childhood cancer, according to investigators from Dana-Farber/Boston Children's Cancer and Blood Disorders Center. While the overall cure rate for ALL is high, about one to two percent of children die during the first month of therapy from treatment complications, primarily infection-related. Senior study investigator: Lewis Silverman, MD.
- Young adults with ALL have survival gain with pediatric regimen
Dana-Farber researchers report that using a pediatric chemotherapy regimen to treat young adults ages 18-50 with acute lymphoblastic leukemia (ALL) significantly improved their outcomes compared to what has historically been achieved with "adult" treatment protocols. Senior author: Richard Stone, MD; first author and study leader: Daniel DeAngelo, MD, PhD.